Submission of supplemental NDA to FDA for Ayvakit for the treatment of indolent systemic mastocytosis
Blueprint Medicines Corporation announced the submission of a supplemental new drug application to the FDA for Ayvakit (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM)
Ayvakit was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95 percent of cases.
The submission includes data from the registrational PIONEER trial, the largest randomized, placebo-controlled clinical study ever conducted in indolent SM. The FDA has granted breakthrough therapy designation to Ayvakit for the treatment of moderate to severe indolent SM.
"This regulatory submission for Ayvakit marks an important milestone to address the medical needs of a broad population of patients with systemic mastocytosis, characterized by debilitating symptoms and lifelong disease burden across multiple organs," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "By targeting the primary driver of SM with Ayvakit, we are seeking to transform treatment beyond symptom-directed therapy, modify the course of disease and ultimately, make a meaningful difference in patients' lives. Our FDA filing marks the first regulatory application seeking approval for the treatment of indolent SM, and we look forward to working closely with the agency toward our goal of bringing Ayvakit to indolent SM patients as quickly as possible".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins